|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, TMEM16A is also expressed on airway epithelium, and TMEM16A <i>agonists</i> are being investigated as novel therapies for cystic fibrosis.
|
31747299 |
2020 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
GISTs with predominant epithelioid cell morphology may pose a diagnostic dilemma therefore in all suspected cases of GIST, immunocytochemistry for c-Kit and/or DOG1 should be employed on cell block preparations to confirm the diagnosis of GIST.
|
31698512 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor cells were positive for p40, p63, cytokeratin 5/6, cytokeratin 7, and cancer antigen 125, but negative for discovered on GIST-1 (DOG1).
|
31177170 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANO1/TMEM16A, a member of Ca<sup>2+</sup> -activated Cl<sup>-</sup> channels (CaCCs), has been demonstrated to promote epithelium-originated cancers and whether it plays a role in the pathogenesis of ovarian cancer is unknown.
|
30243029 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We will survey TMEM16A contribution in cancer prognosis, the origins of its over-expression in cancer cells, the multiple biological functions and molecular pathways regulated by TMEM16A.
|
31279157 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the dysfunction of TMEM16A has been found to be involved in many diseases including cystic fibrosis, various cancers, hypertension, and gastrointestinal motility disorders.
|
30515811 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently it was shown that knockout of TMEM16A in ciliated cells strongly compromises Cl<sup>-</sup> conductance and attenuated mucus secretion, but does not lead to a CF-like lung disease and airway plugging.
|
30761000 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TMEM16A/F proteins may therefore have an impact on disease severity in CF.
|
30915480 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, intratumoral injection of ANO1 siRNA suppressed subcutaneous xenograft tumor growth in nude mice implanted with ovarian cancer SKOV3 cells.
|
30243029 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, Ano1 depletion failed to affect tumor development in a model of colorectal cancer.
|
31383845 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Based on c-kit and DOG-1 immunoreactivity and a PDGFRA mutation (p.Trp559_Arg560del), the tumor was diagnosed as an epithelioid variant GIST.
|
31273885 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nodule was resected in an enucleation procedure; subsequent histopathologic examination revealed a low-grade, spindled cell neoplasm with diffuse immunoreactivity for CD117 (cKit) and DOG1, diagnostic of GIST.
|
31497448 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor showed variable staining in the 2 components with diffuse DOG-1 and CD117 positivity in the WD component and complete absence in the DD foci.
|
31072206 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ANO1 expression was associated with advanced tumor stage and lymph node metastasis, and there was an inverse relationship between miR-9 and ANO1 mRNA expression in CRC specimens, but no significant difference was found between miR-9 and ANO1 expression.
|
30803553 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DOG1 is a calcium-activated chloride channel that has gained attention as a promising drug target due to its involvement in several processes essential for tumor development and progression.
|
31262867 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Although both markers stain positive, DOG1 showed higher score with epithelioid GISTs.
|
30880769 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The nodule was resected in an enucleation procedure; subsequent histopathologic examination revealed a low-grade, spindled cell neoplasm with diffuse immunoreactivity for CD117 (cKit) and DOG1, diagnostic of GIST.
|
31497448 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Based on c-kit and DOG-1 immunoreactivity and a PDGFRA mutation (p.Trp559_Arg560del), the tumor was diagnosed as an epithelioid variant GIST.
|
31273885 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DOG1 is overexpressed in >95% of gastrointestinal stromal tumors (GIST).
|
31262867 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TMEM16A is overexpressed in many cancers, including gastrointestinal stromal tumors, gastric cancer, head and neck squamous cell carcinoma (HNSCC), colon cancer, pancreatic ductal adenocarcinoma, and esophageal cancer.
|
30515811 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Before anoctamins (TMEM16 proteins) were identified as a family of Ca<sup>2+</sup>-activated chloride channels and phospholipid scramblases, the founding member anoctamin 1 (ANO1, TMEM16A) was known as DOG1, a marker protein for gastrointestinal stromal tumors (GIST).
|
30893776 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty years after the discovery of KIT in GISTs, the diagnosis of GISTs became much more accurate by using immunohistochemical (IHC) panel (CD117/DOG1) and molecular analysis (<i>KIT/PDGFRA</i>), both of which constitute the gold standard of diagnosis in GISTs.
|
31100836 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to evaluate the diagnostic ability of ANO1 mRNA in distinguishing GIST patients from healthy subjects.
|
31266974 |
2019 |